Track topics on Twitter Track topics that are important to you
GOODYEAR, AZ--(Marketwired - August 10, 2015) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí" or “the Company”), producer of the highly bioavailable Phytofare®
catechin complex, today announced an amendment to its previously announced agreement with USN Worldwide. By virtue of the amended agreement with USN, the Company will now expand its exclusive Phytofare®
sales to USN and its contract manufacturers to the European Union.
Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí, commented, “We are extremely pleased to expand our agreement with USN into the European market. Obviously it is a huge opportunity for us, as we believe opening up the European market through our expanded relationship with USN will increase the sales of our Phytofare®
catechin complex. As a leader in sports nutrition and wellness, USN understands the benefits of phyto-availability within their product line-up, as well as the need to ensure that customers are getting the maximum potential and benefit from their supplements.”
USN spokesperson, Irma Botes, added, “Customers are demanding more and more from their bodies and from their nutrition supplement partner, and USN remains committed to providing the best products to the global marketplace. Our relationship with Plandaí, which increases the active ingredients’ absorption and residence in the body, gives us a huge competitive advantage -- an advantage our customers have noticed.”
USN (www.usn.co.za) was founded in South Africa in 2000, and it remains a comprehensive health and nutrition supplement brand, driving the forefront of sports nutrition and wellness supplements globally. Rapid expansion and an increasing consumer base have been realized through a commitment to leading product innovation, the highest quality raw material suppliers globally, premium manufacturing facilities and excellent customer support on all levels. All products are formulated with the backing of extensive research and scientific findings, as well as the important clinical background to ensure efficacy and safety. USN continues its global growth strategy, and it is now being sold in pharmacies, FMCG and specialist retailers in over 54 countries on five continents.
Under the terms of the revised three-year agreement, USN has agreed to use Phytofare®
as the exclusive green tea ingredient in their manufactured supplements in exchange for guaranteed pricing and availability concessions from Plandaí.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare®
extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.Marlin MolinaroMarmel Communications, LLCPhone: (702) 434-8692Email: NEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...